GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XTER:BTI) » Definitions » Other Operating Expense

Algernon Pharmaceuticals (XTER:BTI) Other Operating Expense : €-0.00 Mil (TTM As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Other Operating Expense?

Algernon Pharmaceuticals's Other Operating Expense for the three months ended in Feb. 2024 was €-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Feb. 2024 was €-0.00 Mil.

Algernon Pharmaceuticals's quarterly Other Operating Expense declined from Aug. 2023 (€0.00 Mil) to Nov. 2023 (€0.00 Mil) and declined from Nov. 2023 (€0.00 Mil) to Feb. 2024 (€-0.00 Mil).

Algernon Pharmaceuticals's annual Other Operating Expense declined from Aug. 2021 (€0.00 Mil) to Aug. 2022 (€0.00 Mil) and declined from Aug. 2022 (€0.00 Mil) to Aug. 2023 (€-0.00 Mil).


Algernon Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Algernon Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Other Operating Expense Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only - - - - -

Algernon Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Algernon Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (XTER:BTI) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.